Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-10-22
2008-12-09
Wehbe, Anne Marie (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S486000, C530S300000
Reexamination Certificate
active
07462592
ABSTRACT:
This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.
REFERENCES:
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 5041497 (1991-08-01), Bhattacharjee et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5635487 (1997-06-01), Wolf et al.
patent: 5679559 (1997-10-01), Kim et al.
patent: 5780592 (1998-07-01), Mullner et al.
patent: 5925333 (1999-07-01), Krieger et al.
patent: 544292 (1993-06-01), None
patent: 545016 (1993-06-01), None
patent: WO 91/19735 (1991-12-01), None
patent: WO 94/06451 (1994-03-01), None
patent: WO 95/02397 (1995-01-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 95/31557 (1995-11-01), None
patent: WO 96/18372 (1996-06-01), None
patent: WO 96/22765 (1996-08-01), None
patent: WO 96/27379 (1996-09-01), None
patent: WO 97/11682 (1997-04-01), None
patent: WO 97/12052 (1997-04-01), None
patent: WO 98/00556 (1998-01-01), None
Canadian patent application No. 2,264,012, Examination Report mailed Jan. 11, 2007.
Japan patent application No. 10-508319, Office Action mailed Mar. 18, 2008.
Anderson et al., Human gene therapy, Apr. 30, 1998, Nature, vol. 392, pp. 25-30.
Batra et al., “Receptor-Mediated Gene Delivery Emplyong Lectin-Binding Specificity” Gene Therapy 1:255-260, 1994.
Behr et al., “Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy” Bioconjugate Chem. 5:382-389, 1994.
Behr et al., “The Proton Sponge: a Trick to Enter Cells the Viruses did not Exploit” Chimia 51:34-36 (1997).
Chiu et al., Optimizing energy potentials for success in protein tertiary sturcture prediction, May 7, 1998, Folding & Design, vol. 3, pp. 223-228.
Gao and Huang, “Cationic Liposome-Mediated Gene Transfer” Gene Therapy 2:710-722, 1995.
Gao and Huang, “Potentiation of Cationic Liposome-Mediated Gene Transfer Delivery by Polycations” Biochemistry 35:1027-1036, 1996.
Guy et al., “Delivery of DNA into Mammalian Cells by Receptor-Mediated Endocytosis and Gene Therapy” Molecular Biology 3:237-248, 1995.
Hong et al., “Stabilization of Cationic Liposome-Plasmid DNA Complexes by Polyamines and . . . ” FEBS Letters 400:233-237, 1997.
Kabanov and Kabanov, “DNA Complexes with Polycations for the Delivery of Genetic Material into Cells” Bioconjugate Chem. 6:7-20, 1995.
Lasic and Tenpleton, “Liposomes in Gene Therapy” Advanced Drug Delivery Reviews 20:221-226, 1996.
Ledley, “Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products” Human Gene Ther. 6:1129-1144, Sep. 1995.
Legendre et al., “Dioleoylmelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells” Bioconjugate Chem. 8:57-63, 1997.
Liu et al., “Cationic Liposome-Mediated Intravenous Gene Delivery” J. Biological Chemistry 270(42):24864-24870, 1995.
Mastrangelo et al., “Gene Therapy for Human Cancer: an Essay for Clinicians” Seminars in Oncology 23:4-21, 1996.
Merwin et al., “Targeted Delivery of DNA Using Yee(GalNacAH).sub.3, a Synthetic Glycopeptide Ligand . . . ” Bioconjugate Chemistry 5(6):612-620, 1994.
Michael and Curiel, “Strategies to Achieve Targeted Gene Delivery via the Receptor-Mediated Endocytosis Pathway” Gene Therapy 1:223-232, 1994.
Ngo et al., Computational Complexity Protein Structure Prediction, and the Levinthal Parasdox, 1994, vol. 14, pp. 492-495.
Ngo et al., in: The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et ., (ed)., Birkhauser, Boston, MA, pp. 433 and 492-495.
Phillips, “Receptor-Mediated DNA Delivery Approaches to Human Gene Therapy” Biologicals 23:13-16, 1995.
Raz et al., Cationic Lipids Inhibit Intradermal Genetic Vaccination, 1994, pp. 71-75.
Remy et al., “Targeted Gene Transfer into Hepatoma Cells With Lipopolyamine-Condensed DNA Particles . . . ” PNAS USA 92:1744-1748, 1995.
Richter and Zuckerman, “Synthesis of Peptide Nucleic Acids (PNA) by Submonomer Solid-Phase Synthesis” 5(11) : 1159-1162 (1995).
Tomlinson and Rolland, “Controllable Gene Therapy Pharmaceutics of Non-Viral Gene Delivery Systems” J. Controlled Release 39:357-372, 1996.
Verma et al., Gene therapy-promises, problems and prospects, Sep. 18, 1997, Nature, vol. 389, pp. 239-242.
Wagner et al., “DNA-Binding Transferrin Conjugates as Functional Gene-Delivery Agents: . . . ” Bioconjugate Chem. 2:226-231, 1991.
Wagner et al., “Influenza Virus Hemagglutinin HA-2 N-terminal Fusogenic Peptides Augment Gene Transfer by . . . ” PNAS USA 89:7934-7938, 1992.
Wheeler et al., “Converting an Alcohol to an Amine in a Cationic Lipid Dramatically Alters the Co-Lipid Requirement, . . . ” Biochim. et Biophsica Acta. 1280:1-11, 1996.
Cohen Fred E.
Dubois-Stringfellow Nathalie
Dwarki Varavani
Innis Michael A.
Murphy John E.
Austin James
Hong Mei
Novartis Vaccines and Diagnostics Inc.
Sajjadi Fereydoun G
Seka Mark
LandOfFree
Compositions and methods for polynucleotide delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for polynucleotide delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for polynucleotide delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035226